Skip To Main Content
Luiza Barseghyan on Muck Rack

Luiza Barseghyan

As seen in: Preprints.org
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Luiza

Contact Luiza, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Sex Paradox in Papillary Thyroid Carcinoma: Higher Incidence in Women, Poorer Outcomes in Men, and an Emerging Non-Coding RNA Layer

|
By Luiza Barseghyan, Alfred Simental, Olabisi Bamidele
| Preprints.org
Submitted: 23 September 2026 Posted: 24 September 2026 You are already at the latest version Background/Objectives: Papillary thyroid carcinoma (PTC) shows a striking sex disparity: women are diagnosed roughly three times more often than men, yet male sex is an independent risk factor for recurrence, disease progression, and disease-specific mortality once PTC is established.
Open in Who Shared Issue with article?

Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms

|
By Luiza Barseghyan, Iqbal Munir, Steven Chrysafides
| Preprints.org
Submitted: 05 September 2026 Posted: 08 September 2026 You are already at the latest version Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) marketed as Ozempic and Wegovy, is now among the most widely prescribed medications for type 2 diabetes and obesity.
Open in Who Shared Issue with article?

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment Strategy

|
By Joseph M. Cruz, Janice Pakkianathan, Celena R. Yamauchi, Luiza Barseghyan
| Preprints.org
You are already at the latest version Anaplastic thyroid carcinoma (ATC) is the rarest and most aggressive form of thyroid cancer, marked by a poor prognosis and resistance to conventional treatments. Like many malignancies, ATC has a complex genetic landscape, with numerous mutations driving tumor initiation, progression, and therapeutic resistance.
Open in Who Shared Issue with article?
See all 3 articles